To the top

Page Manager: Webmaster
Last update: 9/11/2012 3:13 PM

Tell a friend about this page
Print version

Detection of Circulating … - University of Gothenburg, Sweden Till startsida
Sitemap
To content Read more about how we use cookies on gu.se

Detection of Circulating Tumor DNA in Plasma: A Potential Biomarker for Esophageal Adenocarcinoma

Journal article
Authors M. Egyud
M. Tejani
A. Pennathur
J. Luketich
P. Sridhar
E. Yamada
Anders Ståhlberg
Stefan Filges
P. Krzyzanowski
J. Jackson
I. Kalatskaya
W. Jiao
G. Nielsen
Z. R. Zhou
V. Litle
L. Stein
T. Godfrey
Published in Annals of Thoracic Surgery
Volume 108
Issue 2
Pages 343-349
ISSN 0003-4975
Publication year 2019
Published at Sahlgrenska Cancer Center
Pages 343-349
Language en
Links dx.doi.org/10.1016/j.athoracsur.201...
Keywords cancer, recurrence, mutations, epidemiology, diagnosis, patterns, survival, monitor, exome, Cardiovascular System & Cardiology, Respiratory System, Surgery
Subject categories Cancer and Oncology

Abstract

Background. Recent literature has demonstrated the potential of "liquid biopsy" and detection of circulating tumor (ct)DNA as a cancer biomarker. However, to date there is a lack of data specific to esophageal adenocarcinoma (EAC). This study was conducted to determine how detection and quantification of ctDNA changes with disease burden in patients with EAC and evaluate its potential as a biomarker in this population. Methods. Blood samples were obtained from patients with stage I to IV EAC. Longitudinal blood samples were collected from a subset of patients. Imaging studies and pathology reports were reviewed to determine disease course. Tumor samples were sequenced to identify mutations. Mutations in plasma DNA were detected using custom, barcoded, patient-specific sequencing libraries. Mutations in plasma were quantified, and associations with disease stage and response to therapy were explored. Results. Plasma samples from a final cohort of 38 patients were evaluated. Baseline plasma samples were ctDNA positive for 18 patients (47%) overall, with tumor allele frequencies ranging from 0.05% to 5.30%. Detection frequency of ctDNA and quantity of ctDNA increased with stage. Data from longitudinal samples indicate that ctDNA levels correlate with and precede evidence of response to therapy or recurrence. Conclusions. ctDNA can be detected in plasma of EAC patients and correlates with disease burden. Detection of ctDNA in early-stage EAC is challenging and may limit diagnostic applications. However, our data demonstrate the potential of ctDNA as a dynamic biomarker to monitor treatment response and disease recurrence in patients with EAC. (C) 2019 by The Society of Thoracic Surgeons

Page Manager: Webmaster|Last update: 9/11/2012
Share:

The University of Gothenburg uses cookies to provide you with the best possible user experience. By continuing on this website, you approve of our use of cookies.  What are cookies?

Denna text är utskriven från följande webbsida:
http://www.gu.se/english/research/publication/?languageId=100001&disableRedirect=true&returnUrl=http%3A%2F%2Fwww.gu.se%2Fforskning%2Fpublikation%2F%3FpublicationId%3D282591&publicationId=282591
Utskriftsdatum: 2019-11-15